Tuebingen study on cardiac amyloidosis in aortic stenosis lists Bayer as collaborator
A University Hospital Tuebingen observational study tracking cardiac amyloidosis in aortic valve stenosis patients undergoing TAVI evaluation was first posted August 7, 2026, with Bayer named as a collaborator.
This week's item is a single observational study registered by University Hospital Tuebingen.
- NCT07752732 ("NIS-TAVI-AMY") is a non-interventional study evaluating multimodal imaging biomarkers for the detection and characterization of cardiac amyloidosis in patients with severe AS undergoing TAVI evaluation.1 The study is listed as recruiting, with an actual start date of 2020-01-14 and an estimated primary completion date of 2027-12-31. University Hospital Tuebingen is the lead sponsor, and Bayer is listed as a collaborator.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.